Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype

Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we compare the tumor immune landscape and peripheral T...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wilpe, Sandra, Simnica, Donjetë, Slootbeek, Peter, van Ee, Thomas, Pamidimarri Naga, Samhita, Gorris, Mark A. J., van der Woude, Lieke L., Sultan, Shabaz, Koornstra, Rutger H. T., van Oort, Inge M., Gerritsen, Winald R., Kroeze, Leonie I., Simons, Michiel, van Leenders, Geert J. L. H., Binder, Mascha, de Vries, I. Jolanda M., Mehra, Niven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255222/
https://www.ncbi.nlm.nih.gov/pubmed/35800157
http://dx.doi.org/10.1080/2162402X.2022.2094133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255222/
https://www.ncbi.nlm.nih.gov/pubmed/35800157
http://dx.doi.org/10.1080/2162402X.2022.2094133

Ejemplares similares